Skip to main content

Advertisement

Log in

The Pharmacokinetics of Esmolol in Pediatric Subjects with Supraventricular Arrhythmias

  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Esmolol is often used in the acute management of children with arrhythmias and/or hypertension; however, pharmacokinetic studies of the drug in children have been limited. The objective of this study was to determine the pharmacokinetics of esmolol in children with a history of supraventricular arrhythmias (SVT) who were scheduled for diagnostic electrophysiology study or a catheter ablation procedure. Subjects were stratified into two age groups: 2–11 and 12–16 years. After an episode of stimulated or spontaneous SVT, esmolol was administered intravenously as a 1,000 μg/kg bolus followed by continuous infusion at 300 μg/kg/min. Blood samples were collected before, at 5, 10 and 15 min after the loading dose, and 3, 6, 9, 12, 15 and 20 min after the end of the infusion. Plasma concentration of esmolol was quantitated by a specific LC/MS assay. Pharmacokinetic data were available for 25 subjects. Arterial esmolol concentrations were approximately five times greater than venous concentrations. Esmolol had an extremely short distribution half-life (0.6 min), a rapid terminal elimination half-life (6.9 min), and a rapid clearance (119 ± 51 mL/min/kg) which was not related to subject age or weight. Seventeen of the subjects (63%) converted to normal sinus rhythm in an average of 2 min (range 0–5 min). The pharmacokinetics of esmolol and its efficacy in terminating SVT in children is similar to that observed in adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abrams J, Allen J, Allin D, Anderson J, Anderson S, Blanski L, Chadda K, DiBianco R, Favrot L, Gonzalez J et al. (1985) Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J 110:913–922

    Article  PubMed  CAS  Google Scholar 

  2. Anderson S, Blanski L, Byrd RC, Das G, Engler R, Laddu A, Lee R, Rajfer S, Schroeder J, Steck JD et al. (1986) Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The esmolol vs placebo multicenter study group. Am Heart J 111:42–48

    Article  PubMed  CAS  Google Scholar 

  3. de Bruijn NP, Reves JG, Croughwell N, Clements F, Drissel DA (1987) Pharmacokinetics of esmolol in anesthetized patients receiving chronic beta blocker therapy. Anesthesiology 66:323–326

    Article  PubMed  Google Scholar 

  4. Buchi KN, Rollins DE, Tolman KG, Achari R, Drissel D, Hulse JD (1987) Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol 27:880–884

    PubMed  CAS  Google Scholar 

  5. Cuneo BF, Zales VR, Blahunka PC, Benson DW Jr (1994) Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children. Pediatr Cardiol 15:296–301

    Article  PubMed  CAS  Google Scholar 

  6. Bruns LA, Canter CE (2002) Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? Paediatr Drugs 4:771–778

    PubMed  Google Scholar 

  7. Flaherty JF, Wong B, La Follette G, Warnock DG, Hulse JD, Gambertoglio JG (1989) Pharmacokinetics of esmolol and asl-8123 in renal failure. Clin Pharmacol Ther 45:321–327

    Article  PubMed  CAS  Google Scholar 

  8. Hebbar AK, Hueston WJ (2002) Management of common arrhythmias: Part ii. Ventricular arrhythmias and arrhythmias in special populations. Am Fam Physician 65:2491–2496

    PubMed  Google Scholar 

  9. Jacobs JR, Croughwell ND, Goodman DK, White WD, Reves JG (1993) Effect of hypothermia and sampling site on blood esmolol concentrations. J Clin Pharmacol 33:360–365

    PubMed  CAS  Google Scholar 

  10. McLeod KA (2001) Dysautonomia and neurocardiogenic syncope. Curr Opin Cardiol 16:92–96

    Article  PubMed  CAS  Google Scholar 

  11. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML (2000) Effectiveness and limitations of beta-blocker therapy in congenital long-qt syndrome. Circulation 101:616–623

    PubMed  CAS  Google Scholar 

  12. Sartory G, Muller B, Metsch J, Pothmann R (1998) A comparison of psychological and pharmacological treatment of pediatric migraine. Behav Res Ther 36:1155–1170

    Article  PubMed  CAS  Google Scholar 

  13. Seggewiss H, Rigopoulos A (2003) Management of hypertrophic cardiomyopathy in children. Paediatr Drugs 5:663–672

    Article  PubMed  Google Scholar 

  14. Shaddy RE (2001) Beta-adrenergic receptor blockers as therapy in pediatric chronic heart failure. Minerva Pediatr 53:297–304

    PubMed  CAS  Google Scholar 

  15. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, Cunningham RJ (2002) Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 17:345–350

    Article  PubMed  Google Scholar 

  16. Stefanovski D, Moate PJ, Boston RC (2003) Winsaam: a windows-based compartmental modeling system. Metabolism 52:1153–1166

    Article  PubMed  CAS  Google Scholar 

  17. Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM (1983) Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 34:427–434

    Article  PubMed  CAS  Google Scholar 

  18. Wiest D (1995) Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet 28:190–202

    PubMed  CAS  Google Scholar 

  19. Wiest DB, Trippel DL, Gillette PC, Garner SS (1991) Pharmacokinetics of esmolol in children. Clin Pharmacol Ther 49:618–623

    Article  PubMed  CAS  Google Scholar 

  20. Wiest DB, Garner SS, Uber WE, Sade RM, Gillette PC (1993) Pharmacokinetics of esmolol in pediatric post-cardiac surgery patients [abstr]. Clin Pharmacol Ther 53:145

    Google Scholar 

  21. Wiest DB, Garner SS, Uber WE, Sade RM (1998) Esmolol for the management of pediatric hypertension after cardiac operations. J Thorac Cardiovasc Surg 115:890–897

    Article  PubMed  CAS  Google Scholar 

  22. Zuppa AF, Shi H, Adamson PC (2003) Liquid chromatography-electrospray mass spectrometry (lc-ms) method for determination of esmolol concentration in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 796:293–301

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work supported by Baxter Healthcare Corporation and in part by a grant from the National Institutes of Health Pediatric Pharmacology Research Unit (U10 HD37255).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter C. Adamson.

Appendix

Appendix

Study concept and design: Adamson, Rhodes and Schreiner;

Advisory board: Dick, Saul and Epstein;

Acquisition of Data: Rhodes, Dick, Saul and Epstein;

Drafting of the manuscript: Adamson and Schreiner

Critical revision of the manuscript: Rhodes, Dick, Saul, Epstein, Moate and Boston

Statistical analysis: Cheng-Tao Chang, PhD (Baxter)

Pharmacology analysis: Adamson, Moate, Boston

Administrative support: Sarah Reedy, Eileen Dorsey, Meryl Poku (CCRi), Joyce Green (Baxter)

Study supervision: Schreiner, Marc Hoffman, MD (Baxter)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adamson, P.C., Rhodes, L.A., Saul, J.P. et al. The Pharmacokinetics of Esmolol in Pediatric Subjects with Supraventricular Arrhythmias. Pediatr Cardiol 27, 420–427 (2006). https://doi.org/10.1007/s00246-006-1162-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-006-1162-1

Keywords

Navigation